Paper No. 8
`Filed: January 8, 2020
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`_________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_________________
`
`PROLLENIUM US INC.,
`
`Petitioner,
`
`v.
`
`ALLERGAN INDUSTRIE, SAS,
`
`Patent Owner.
`
`_________________
`
`Case IPR2020-00084
`Patent 9,089,519
`_________________
`
`PETITIONER’S MOTION FOR ADMISSION PRO HAC VICE OF
`JOHN W. HARBIN
`
`
`Filed: January 8, 2020
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`_________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_________________
`
`PROLLENIUM US INC.,
`
`Petitioner,
`
`v.
`
`ALLERGAN INDUSTRIE, SAS,
`
`Patent Owner.
`
`_________________
`
`Case IPR2020-00084
`Patent 9,089,519
`_________________
`
`PETITIONER’S MOTION FOR ADMISSION PRO HAC VICE OF
`JOHN W. HARBIN
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.10, Petitioner requests that the board admit John
`
`W. Harbin pro hac vice in this proceeding.
`
`The Board may recognize counsel pro hac vice during a proceeding on a
`
`showing of good cause. “[W]here lead counsel is a registered practitioner, a motion
`
`to appear pro hac vice may be granted upon a showing that counsel is an
`
`experienced litigation attorney and has an established familiarity with the subject
`
`matter at issue in the proceeding.” 37 C.F.R. § 42.10(c).
`
`Here, lead counsel Christopher J. Curfman is a registered practitioner. Mr.
`
`Harbin has over 25 years of experience in patent litigation, and he is familiar with
`
`the subject matter at issue in this proceeding. Accompanying this motion is the
`
`Declaration of John W. Harbin, where Mr. Harbin attests to his experience and
`
`familiarity. See generally Harbin Decl. (Ex. 1084). Specifically, Mr. Harbin attests
`
`that:
`
` he has been practicing intellectual property litigation, including patent
`
`litigation, for more than 25 years;
`
` he has been lead trial counsel on numerous patent litigation cases;
`
` he has previously represented the Petitioner on patent-related matters;
`
`and
`
` he is lead counsel in the related district court action where the Patent
`
`Owner has asserted the challenged patents against Petitioner.
`
`1
`
`
`
`
`
`Ex. 1084 ¶¶ 2, 9.
`
`These facts establish good cause to recognize Mr. Harbin in this proceeding.
`
`Respectfully submitted,
`
`/Christopher L. Curfman/
`Christopher L. Curfman (Reg. No. 52,787)
`
`
`
`
`
`2
`
`
`
`
`
`
`
`Exhibit
`No.
`1001
`
`1002
`1003
`1004
`
`1005
`
`1006
`
`1007
`
`1008
`
`1009
`
`1010
`
`1011
`
`1012
`
`PETITIONER’S EXHIBIT LIST
`
`Description
`
`U.S. Patent No. 9,089,519 to Lebreton
`(issued July 28, 2015) (the ’519 patent or the challenged patent)
`Declaration of Dale Devore, Ph.D.
`CV of Dale Devore, Ph.D.
`Steven Fagien & Arnold W. Klein, A Brief Overview and History of
`Temporary Fillers: Evolution, Advantages, and Limitations, Plastic
`and Reconstructive Surgery, Vol. 120 Supplement 6S, 8S–16S (Nov.
`2007)
`Mary P. Lupo, Hyaluronic Acid Fillers in Facial Rejuvenation,
`Seminars in Cutaneous Medicine and Surgery, Vol. 25, No. 6, 122–
`126 (Sept. 2006)
`Seth L. Matarraso, Understanding and Using Hyaluronic Acid,
`Aesthetic Surgery Journal Vol. 24, No. 4, 361–364 (July/August 2004)
`Rhoda S. Narins & Paul H. Bowman, Injectable Skin Fillers, Clinics
`in Plastic Surgery, Vol. 32, Issue 2, 151–162 (April 2005)
`Clifford P. Clark III, Animal-Based Hyaluronic Acid Fillers: Scientific
`and Technical Considerations, Plastic and Reconstructive Surgery,
`Vol. 120 Supplement 6S, 27S-32S (Nov. 2007)
`Kevin C. Smith, Practical Use of Juvéderm: Early Experience, Plastic
`and Reconstructive Surgery, Vol. 120 Supplement 6S, 67S-73S (Nov.
`2007)
`Rod J. Rohrich, et al., The Role of Hyaluronic Acid Fillers (Restylane)
`in Facial Cosmetic Surgery: Review and Technical Considerations,
`Plastic and Reconstructive Surgery, Vol. 120 Supplement 6S, 41S-54S
`(Nov. 2007)
`Michael H. Gold, Use of Hyaluronic Acid Fillers for the Treatment of
`the Aging Face, Clinical Interventions in Aging, Vol. 2, Issue 3, 369-
`376 (Sept. 2007)
`Brian M. Kinney, Injecting Puragen Plus Into the Nasolabial Folds:
`Preliminary Observations of FDA Trial, Aesthetic Surgery Journal,
`Vol. 26, Issue 6, 741-748 (Nov. 2006), also available at
`https://academic.oup.com/asj/article/26/6/741/238376
`
`3
`
`
`
`
`
`Exhibit
`No.
`1013
`
`1014
`
`1015
`
`1016
`
`1017
`
`1018
`
`1019
`
`1020
`1021
`
`Description
`
`U.S. Provisional App. Serial No. 61/085,956 (filed Aug. 4, 2008)
`(priority document for challenged patent)
`Gary D. Monheit & Chad L. Prather, Juvéderm: A Hyaluronic Acid
`Dermal Filler, Journal of Drugs in Dermatology, Vol. 6, Issue 11,
`1091-1095 (Nov. 2007)
`Leslie S. Baumann, et al., Comparison of Smooth-Gel Hyaluronic
`Acid Dermal Fillers with Cross-linked Bovine Collagen: A
`Multicenter, Double-masked, Randomized, Within-Subject Study,
`Dermatologic Surgery, Vol. 33 Supplement 2, S128-S135 (Dec. 2007)
`Deborah, S. Sarnoff, et al., Comparison of Filling Agents for Lip
`Augmentation, Aesthetic Surgery Journal, Vol. 28, Issue 5, 556-563
`(September/October 2008)
`Michael S. McCracken, et al., Hyaluronic Acid Gel (Restylane) Filler
`for Facial Rhytids: Lessons Learned From American Society of
`Ophthalmic Plastic and Reconstructive Surgery Member Treatment of
`286 Patients, Ophthalmic Plastic and Reconstructive Surgery, Vol. 22,
`Issue 3, 188-191 (May-Jun 2006)
`Barry L. Eppley & Babak Dadvand, Injectable Soft-Tissue Fillers:
`Clinical Overview, Plastic and Reconstructive Surgery, Vol. 118, Issue
`4, 98e-106e (Sept. 15, 2006)
`M.J.A. Sapijaszko, Dermal Fillers: Ever-Expanding Options for
`Esthetic Use, Skin Therapy Letter, Vol. 12, No. 8, 4–7 (Oct. 2007)
`Update on Drugs, Skin Therapy Letter, Vol. 13, No. 3, 8 (Apr. 2008)
`Carol A. Toth, et al., Preclinical evaluation of a novel hyaluronic acid
`28 mg/ml lidocaine 0.3% stable combination product, (abstract),
`Journal of the American Academy of Dermatology, Vol. 56, No. 2,
`AB94 (Feb. 2007), Abstract P1039
`
`and
`
`C. William Hanke, et al., Effectiveness and durability of a hyaluronic
`acid 28 mg/ml, lidocaine 0.3% stable combination product as
`demonstrated in a multicenter, randomized trial (abstract), Journal of
`the American Academy of Dermatology, Vol. 56, No. 2, AB94 (Feb.
`2007), Abstract P1040
`
`4
`
`
`
`
`
`Exhibit
`No.
`1022
`
`1023
`
`1024
`1025
`
`1026
`
`1027
`
`1028
`
`1029
`
`1030
`
`1031
`1032
`
`1033
`
`1034
`1035
`
`Description
`
`Gary D. Monheit, Hyaluronic Acid Fillers: Hylaform and Captique,
`Facial Plastic Surgery Clinics, Vol. 15, No. 1, 77 (Feb. 2007)
`Excerpts from file history of U.S. Application 12/393,884 (filed
`2/26/2009)
`Lebreton Declaration
`Yu jia Cui, et al., The Comparison of Physicochemical Properties of
`Four Cross-Linked Sodium Hyaluronate Gels with Different Cross-
`Linking Agents, Advanced Materials Research, Vols. 396-398, 1506-
`1512 (2012)
`Excerpts from file history of U.S. Application 13/419,079 (filed
`3/13/2012)
`Claim Construction Order, Allergan USA, Inc. v. Medicis Aethetics,
`Inc., No. 8:13-cv-01436-AG-JPR, slip op. (Aug. 12, 2014), ECF No.
`79, also available at 2014 WL 5488895
`U.S. Provisional App. Serial No. 61/087,934 (filed Aug. 11, 2008)
`(priority document for challenged patent)
`U.S. Patent Publication No. 2006/0194758 to Lebreton (Lebreton),
`published Aug. 31, 2006
`U.S. Patent Publication No. 2005/0136122 to Sadozai et al. (Sadozai),
`published June 23, 2005
`CTA Product Insert (“Label”)
`Amy E. Newburger, Cosmetic Medical Devices and Their FDA
`Regulation, Archives of Dermatology, Vol. 142, 225–228 (Feb. 2006)
`Excerpts from file history of U.S. Application 12/393,768 (filed
`2/26/2009)
`RESERVED
`Inja Bogdan Allemann & Leslie Baumann, Hyaluronic Acid Gel
`(Juvedérm) Preparations in the Treatment of Facial Wrinkles and
`Folds, Clinical Interventions in Aging, Vol. 3, Issue 4, 629–634 (Dec.
`2008)
`
`5
`
`
`
`
`
`Exhibit
`No.
`1036
`
`1037
`
`1038
`1039
`
`1040
`
`1041–
`1043
`1044
`
`1045
`
`1046
`1047
`
`1048
`
`1049
`
`1050
`1051
`1052
`
`Description
`
`Åke Öhrlund, et al., Extrusion Force and Syringe Dimensions of Two
`Hyaluronic Acid Dermal Fillers, 8th Anti-aging Medicine World
`Congress (AMWC) (April 2010)
`U.S. Patent Publication No. 2008/0188441 to Reinmuller et al.
`(Reinmuller 2008), published Aug. 7, 2008, and filed in the U.S. on
`July 14, 2006
`RESERVED
`Samuel J. Falcone & Richard A. Berg, Crosslinked Hyaluronic Acid
`Dermal Fillers: A Comparison of Rheological Properties, Journal of
`Biomedical Materials Research, Vol. 87A, Issue 1, 264–271 (Jan. 15,
`2008)
`Excerpts from file history of U.S. Application 13/746,170 (filed
`1/21/2013)
`RESERVED
`
`U.S. Provisional App. Serial No. 61/096,278 (filed Sept. 11, 2008)
`(priority document for challenged patent)
`Ahmet Tezel & Glenn H. Fredrickson, The Science of Hyaluronic Acid
`Dermal Fillers, Journal of Cosmetic and Laser Therapy, Vol. 10, Issue
`1, 35-42 (Mar. 2008)
`Update on Drugs, Skin Therapy Letter, Vol. 12, No. 7, 8 (Sept. 2007)
`U.S. Patent Publication No. 2005/0271729 to Wang, published Dec. 8,
`2005
`U.S. Patent No. 6,521,223 to Calias et al. (issued Feb. 18, 2003)
`(Calias)
`Excerpts from file history of U.S. Application 14/242,747 (filed
`4/1/2014)
`CTA Summary of Safety and Effectiveness, December 20, 2006
`RESERVED
`Prevelle Silk; PMA P030032, February 26, 2008
`
`6
`
`
`
`
`
`Exhibit
`No.
`1053
`
`1054
`1055
`1056
`
`1057
`
`1058
`
`1059
`
`1060
`
`1061
`1062
`
`1063
`
`1064
`
`1065
`
`1066–
`1069
`
`Description
`
`Mentor Corp. Announces FDA Approval of Prevelle Silk,
`https://www.businesswire.com/news/home/20080321005064/en/Ment
`or-Corporation-Announces-FDA-Approval-Prevelle-Silk (Mar. 21,
`2008)
`RESERVED
`RESERVED
`Robert Stern, et al., The Many Ways to Cleave Hyaluronan,
`Biotechnology Advances, Vol. 25, Issue 6, 537–557
`(November/December 2007)
`J.W. Kuo, Practical Aspects of Hyaluronan Based Medical Products,
`CRC Press, Taylor & Francis Group, 2006, pp. 34-43, 79-93
`U.S. Patent Publication No. 2005/0250939 to Zhao (Zhao), published
`Nov. 10, 2005
`U.S. Patent No. 5,731,298 to Reinmuller (issued Mar. 24, 1998)
`(Reinmuller 298)
`Premarket Approval (PMA) Supplement Summary Review Memo for
`P050047/S005 (Jan. 6. 2010), available at
`https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id
`=P050047S005
`U.S. Provisional App. Serial No. 60/953,661 (filed Aug. 2, 2007)
`U.S. Patent No. 4,605,691 to Balazs et al. (issued Aug. 12, 1986)
`(Balazs 691)
`U.S. Patent No. 4,713,448 to Balazs et al. (issued Dec. 15, 1987)
`(Balazs 448)
`Excerpts from file history of U.S. Application 13/891,052 (filed
`5/9/2013)
`Transcript of Claim Construction Hearing, Allergan USA, Inc. v.
`Medicis Aethetics, Inc., No. 8:13-cv-01436-AG-JPR (Aug. 12, 2014),
`ECF No. 81
`RESERVED
`
`7
`
`
`
`
`
`Exhibit
`No.
`1070
`
`1071
`1072
`
`1073
`
`1074
`
`1075
`
`1076
`
`1077
`
`1078
`
`1079
`
`1080
`1081
`
`Description
`
`Susan H. Weinkle, et al., A multi-center, double-blind, randomized
`controlled study of the safety and effectiveness of Juvéderm®
`injectable gel with and without lidocaine, Journal of Cosmetic
`Dermatology, Vol. 8, No. 3, 205-2010 (Sept. 2009), also available at
`https://onlinelibrary.wiley.com/doi/10.1111/j.1473-2165.2009.00451.x
`RESERVED
`U.S. Patent Publication No. 2010/0028438 to Lebreton (‘’438),
`published June 23, 2005
`Update on Drugs, Skin Therapy Letter, Vol. 15, No. 3, 6 (March
`2010)
`
`Premarket Approval (PMA) Summary Review Memo for P050047
`(June 2, 2006), available at
`https://www.accessdata.fda.gov/cdrh_docs/pdf5/P050047B.pdf
`Food and Drug Administration, Medical Devices; Availability of
`Safety and Effectiveness Summaries for Premarket Approval
`Applications, 71 Fed. Reg. 56,157 (September 26, 2006)
`Update on Drugs, Skin Therapy Letter, Vol. 11, No. 6, 10 (July-
`August 2006)
`January 7, 2010, FDA Letter to Allergan, available at
`https://www.accessdata.fda.gov/cdrh_docs/pdf5/P050047S005A.pdf
`Gary D. Monheit et al., Novel Hyaluronic Acid Dermal Filler: Dermal
`Gel Extra Physical Properties and Clinical Outcomes, Dermatologic
`Surgery, Vol. 36, No. S3, 1833-1841 (Nov. 2010)
`Lynnelle Smith et al., Hyaluronic acid dermal fillers: can adjunctive
`lidocaine improve patient satisfaction without decreasing efficacy or
`duration?, Patient Preference and Adherence, Vol. 5, 133-139 (Mar.
`14, 2011)
`Hylaform – Instructions for Use - USA
`Restylane Summary of Safety and Effectiveness, March 25, 2005,
`available at
`https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id
`=P140029
`
`8
`
`
`
`Exhibit
`No.
`1082
`1083
`1084
`
`
`
`
`
`
`Description
`
`U.S. Patent No. 8,357,795 to Lebreton. (issued Jan. 22, 2013)
`U.S. Patent No. 6,921,819 to Piron et al. (issued Jul. 26, 2005)
`Declaration of John W. Harbin In Support of Motion for Admission
`Pro Hac Vice
`
`
`
`9
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. §§ 42.6(e)(4) and consent of the Patent Owner, I certify
`that on January 8, 2020, a copy of Petitioner’s Motion for Admission Pro Hac Vice
`of John W. Harbin and related exhibit was served on the counsel of record by
`email to IPR13351-0081IP1@fr.com.
`
`
`/Margaret A. Cogburn/
`Margaret A. Cogburn
`Meunier Carlin & Curfman LLC
`999 Peachtree St. NE, Suite 1300
`Atlanta, GA 30309
`(404) 645-7700
`
`10
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
